GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Float Percentage Of Total Shares Outstanding

Merus NV (STU:2GH) Float Percentage Of Total Shares Outstanding : 99.43% (As of Jun. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Merus NV Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Merus NV's float shares is 66.99 Mil. Merus NV's total shares outstanding is 67.37 Mil. Merus NV's float percentage of total shares outstanding is 99.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Merus NV's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Merus NV's Institutional Ownership is 24.77%.

Merus NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Merus NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=66.99/67.37
=99.43%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merus NV (STU:2GH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (STU:2GH) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ABCL CVAC RYZB HRMY AGIO ZNTL RXRX MNKD TGTX SAGE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MRUS:USA 2GH:Germany
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Website
https://www.merus.nl
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV (STU:2GH) Headlines

No Headlines